CGS-authored
The California Institute for Regenerative Medicine, the Emeryville-based voter-created agency overseeing $3 billion for stem cell research, has adopted interim conflict of interest rules to govern the body.
The rules, approved by the institute's board at a meeting in Los Angeles on April 7, are designed to prevent real, potential or apparent conflicts of interest, the institute said.
"The California stem cell agency is committed to strong and effective conflict of interest policies," said ICOC Chairman Robert Klein. "The institute and its governing board are dedicated to complying with stringent conflict of interest and ethics policies in the interest of advancing science, medicine and the public good."
The measure follows a campaign from critics concerned about inadequate safeguards to prevent conflicts of interest.
A day before the board adopted the new guidelines, the Oakland-based Center for Genetics and Society charged that seven members on the board of the institute have significant business ties to companies connected to stem cell research. These relationships include substantial equity investments and board memberships and may pose personal financial conflicts of interest, the organization said...
The rules, approved by the institute's board at a meeting in Los Angeles on April 7, are designed to prevent real, potential or apparent conflicts of interest, the institute said.
"The California stem cell agency is committed to strong and effective conflict of interest policies," said ICOC Chairman Robert Klein. "The institute and its governing board are dedicated to complying with stringent conflict of interest and ethics policies in the interest of advancing science, medicine and the public good."
The measure follows a campaign from critics concerned about inadequate safeguards to prevent conflicts of interest.
A day before the board adopted the new guidelines, the Oakland-based Center for Genetics and Society charged that seven members on the board of the institute have significant business ties to companies connected to stem cell research. These relationships include substantial equity investments and board memberships and may pose personal financial conflicts of interest, the organization said...